Ireland
--:--IST
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
Texas 87 California 67 Florida 57 New York 50 Michigan 43
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines10 OncoC4, Inc.3 TORL Biotherapeutics, LLC3 EMD Serono Research & Development Institute, Inc.3 OBI Pharma, Inc2
State
Texas87 California67 Florida57 New York50 Michigan43
All 42 states
Target enrolment
to

Trials with a site in Texas

87 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
NCT07839819Advanced Solid Tumor
DrugsPM54·Doxorubicin·Irinotecan
PharmaMar
Phase 1/2
231
Nebraska, Texas
2026-11-12
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
NCT07408258Advanced Solid Tumor
OncoC4, Inc.
Phase 1
20
New York, Pennsylvania, Texas
2026-08-10
Recruiting
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT07749586Advanced Solid Tumor
DrugPembrolizumab
Arvinas Inc.
Phase 1/2
499
North Carolina, Texas, Virginia
2026-07-29
By invitation
Gotistobart Long Term Extension (LTE) Study
NCT07659379Advanced Solid Tumor
DrugGotistobart
OncoC4, Inc.
Phase 3
20
Texas
2026-07-28
Recruiting
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
InduPro, Inc.
Phase 1/2
132
California, Florida, Indiana, New York, Texas
2026-07-08
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Massachusetts, Tennessee, Texas, Utah
2026-03-19
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen
Phase 1/2
102
Michigan, Tennessee, Texas
2026-02-06
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
DrugBG-75202
BeOne Medicines
Phase 1
86
Alabama, Connecticut, Missouri, Texas, Washington
2025-12-11
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
DrugsBGB-43395·Fulvestrant
BeOne Medicines
Phase 1
105
Alabama, California, Connecticut, Maryland, Massachusetts, Texas, Wisconsin
2025-12-11
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Texas, Virginia
2025-11-10
Recruiting
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
NCT07166601Advanced Solid Tumor
DrugsMFOLFIRINOX·Pembrolizumab
EMD Serono Research & Development Institute, Inc.
Phase 1
77
Connecticut, New York, Texas
2025-10-10
Recruiting
A Study of DS5361b in Participants With Advanced Solid Tumors
NCT07182591Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Daiichi Sankyo
Phase 1
192
Florida, Rhode Island, Texas, Virginia
2025-10-02
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
DrugsAdrucil·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
NCT07128303Advanced Solid Tumor
DrugsPemetrexed·Carboplatin·Pembrolizumab
Gilead Sciences
Phase 1
476
Massachusetts, Texas, Virginia
2025-08-28
Recruiting
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
NCT07124117Advanced Solid Tumor
OBI Pharma, Inc
Phase 1/2
147
California, Texas
2025-08-04
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Florida, Pennsylvania, South Dakota, Texas, Washington
2025-03-18
Active, closed
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT06833008Advanced Solid Tumor
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Recruiting
ARC101 in Advanced Solid Tumors
NCT06672185Advanced Solid Tumor
Third Arc Bio
Phase 1
70
Massachusetts, Michigan, Texas
2025-02-05
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185Advanced Solid Tumor
BioNTech SE
Phase 1/2
248
Kentucky, Michigan, North Carolina, Rhode Island, South Carolina, Texas
2025-01-13
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
DrugBGB-58067
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugR-DXd
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
California, Connecticut, Minnesota, Texas, Washington, Wisconsin
2024-12-09
Recruiting
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
NCT06597721Advanced Solid Tumor, PDAC, HNSCC
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
65
Massachusetts, New York, Texas
2024-11-08
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
New Jersey, Texas, Virginia, Wisconsin
2024-10-18
Recruiting
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
NCT06525298Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
DrugsTrastuzumab deruxtecan·Olaparib
Eisbach Bio GmbH
Phase 1/2
144
Texas
2024-09-09
Active, closed
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
NCT06260774Advanced Solid Tumor
TransCode Therapeutics
Phase 1/2
16
Texas, Utah, Virginia
2024-09-05
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359Advanced Solid Tumor
OncoC4, Inc.
Phase 1
72
California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah
2024-08-23
Recruiting
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
DrugsYervoy·Ipilimumab·Opdivo·Nivolumab
7 Hills Pharma, LLC
Phase 1/2
126
Colorado, Florida, New Hampshire, Rhode Island, Texas
2024-08-23
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Active, closed
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
NCT06421935Advanced Solid Tumor
DrugsHRS-1167·Tuvusertib·Prednisone/Prednisolone·Abiraterone
EMD Serono Research & Development Institute, Inc.
Phase 1
60
New York, Texas
2024-08-07
Recruiting
SW-682 in Advanced Solid Tumors
NCT06251310Advanced Solid Tumor, Mesothelioma, Malignant
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 1
186
Arizona, California, Ohio, Oregon, Texas
2024-07-31
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Recruiting
Study of APR-1051 in Patients With Advanced Solid Tumors
NCT06260514Advanced Solid Tumor
Aprea Therapeutics
Phase 1
90
Ohio, Texas, Virginia
2024-06-13
Active, closed
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
NCT06480240Advanced Solid Tumor
OBI Pharma, Inc
Phase 1/2
117
California, Michigan, Texas, Virginia
2024-06-12
Active, closed
QTX3046 in Patients With KRAS G12D Mutations
NCT06428500Advanced Solid Tumor
Quanta Therapeutics
Phase 1
240
Michigan, North Carolina, Texas, Utah
2024-05-30
Recruiting
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT06249048Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Strand Therapeutics Inc.
Phase 1/2
108
Arizona, California, Ohio, Pennsylvania, Texas, Utah
2024-05-03
Recruiting
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
NCT06163391Advanced Solid Tumor, Metastatic Solid Tumor
SOTIO Biotech AG
Phase 1
40
Texas
2024-05-01
Active, closed
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06328673Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
D2M Biotherapeutics Inc.
Phase 1
160
Texas
2024-04-09
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Florida, Georgia, Massachusetts, Missouri, New York, Texas
2024-03-05
Recruiting
SNV1521 in Participants With Advanced Solid Tumors
NCT06220864Advanced Solid Tumor
DrugsDB-1310·Abiraterone·Darolutamide
Synnovation Therapeutics, Inc.
Phase 1
400
Connecticut, Pennsylvania, Tennessee, Texas, Utah
2024-02-23
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Arizona, California, Florida, Missouri, Texas, Washington
2024-01-18
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
NCT06187402Advanced Solid Tumor
DrugLM-24C5
LaNova Medicines Limited
Phase 1/2
49
California, Florida, Indiana, Ohio, Texas, Virginia
2023-12-20
Recruiting
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223Advanced Solid Tumor
DrugPembrolizumab
1ST Biotherapeutics, Inc.
Phase 1/2
151
Ohio, Texas, Virginia, Washington
2023-12-13
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Recruiting
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050Advanced Solid Tumor, Metastatic Solid Tumor
DrugPembrolizumab
Jazz Pharmaceuticals
Phase 1
177
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2023-11-07
Recruiting
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
DrugHCB101
FBD Biologics Limited
Phase 1
80
Florida, North Carolina, South Carolina, Texas
2023-10-02
Active, closed
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826Advanced Solid Tumor, Colorectal Cancer
TORL Biotherapeutics, LLC
Phase 1
70
California, Colorado, Indiana, Missouri, Tennessee, Texas
2023-09-29
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2
430
Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas
2023-08-30
Recruiting
AMT-116 in Patients With Advanced Solid Tumors
NCT05725291Advanced Solid Tumor
DrugAMT-116
Multitude Therapeutics Inc.
Phase 1
80
Colorado, Texas
2023-07-25
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
DrugOlaparib
Artios Pharma Ltd
Phase 1/2
181
Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
2023-06-30
Active, closed
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer
DrugsOlaparib·Ipilimumab
Lantern Pharma Inc.
Phase 1/2
64
Arkansas, Indiana, Kentucky, Maryland, Pennsylvania, Texas, Utah
2023-06-09
Recruiting
XTX301 in Patients With Advanced Solid Tumors
NCT05684965Advanced Solid Tumor
Xilio Development, Inc.
Phase 1/2
358
California, Connecticut, Minnesota, Missouri, New Jersey, Ohio, Pennsylvania, Texas
2023-05-11
Recruiting
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
NCT05841563Advanced Solid Tumor
DrugPM54
PharmaMar
Phase 1
125
Texas
2023-04-28
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Recruiting
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
NCT05661461Tumor, Solid, Tumor, Advanced Solid Tumor
DrugNab-sirolimus
Aadi Bioscience, Inc.
Phase 1
28
Texas, Utah
2022-11-23
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Arkansas, California, Florida, Maryland, Massachusetts, New York, Tennessee, Texas
2022-09-19
Active, closed
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
NCT05378425Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
DrugsKeytruda·Pembrolizumab
Nectin Therapeutics Ltd
Phase 1
90
California, Louisiana, Texas
2022-09-01
Recruiting
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321Advanced Solid Tumor, NSCLC
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Indiana, Texas, Washington
2022-08-25
Recruiting
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
NCT05329103Advanced Solid Tumor
Peel Therapeutics Inc
Phase 1
65
Arizona, California, North Carolina, Pennsylvania, Rhode Island, Texas, Utah, Virginia
2022-07-11
Active, closed
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714Advanced Solid Tumor, Breast Cancer
DrugsCFI-402257·Fulvestrant
Treadwell Therapeutics, Inc
Phase 1/2
44
Ohio, Texas, Utah, Virginia
2022-05-27
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
DrugsAvelumab·Aldesleukin·Nivolumab
Aulos Bioscience, Inc.
Phase 1/2
159
Florida, Michigan, Minnesota, Missouri, North Carolina, Tennessee, Texas, Utah
2022-04-04
Active, closed
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
NCT05159700Advanced Solid Tumor, Advanced Solid Malignancies
DrugPRJ1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1
39
Colorado, Florida, Ohio, Texas, Virginia
2022-03-31
Recruiting
A Study in Patients With Advanced Cancers
NCT05320588Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
DrugsKeytruda·Pembrolizumab
BiOneCure Therapeutics Inc.
Phase 1/2
332
Texas, Virginia
2022-03-25
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
NCT05269316Solid Tumor, Advanced Solid Tumor
Impact Therapeutics, Inc.
Phase 1/2
61
New Jersey, New York, South Carolina, Texas
2022-02-11
Active, closed
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
NCT05156866Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
TORL Biotherapeutics, LLC
Phase 1
163
California, Indiana, Missouri, Texas
2022-02-02
Recruiting
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
NCT05204862Advanced Solid Tumor
DrugTU2218
TiumBio Co., Ltd.
Phase 1/2
240
Texas
2021-12-02
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
DrugTORL-1-23
TORL Biotherapeutics, LLC
Phase 1
90
California, Kentucky, Minnesota, New York, Ohio, Texas, Virginia
2021-11-17
Active, closed
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT05163041Advanced Solid Tumor
DrugNivolumab
BicycleTx Limited
Phase 1/2
200
Iowa, New York, Ohio, Pennsylvania, Texas, Virginia
2021-11-02
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
DrugsKeytruda·Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2
115
California, Florida, Georgia, Michigan, Texas
2021-08-27
Active, closed
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
NCT05007782Advanced Solid Tumor
DrugsDenikitug·Zimberelimab
Gilead Sciences
Phase 1
304
California, Connecticut, Massachusetts, Tennessee, Texas, Wisconsin
2021-08-18
Recruiting
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT04872166Advanced Solid Tumor, Metastatic Breast Cancer
DrugBTX-A51
Edgewood Oncology Inc.
Phase 1
112
Florida, Ohio, Tennessee, Texas
2021-06-07
Recruiting
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
NCT04762641Advanced Solid Tumor
ABL Bio, Inc.
Phase 1
100
California, Colorado, Texas
2021-04-01
Active, closed
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT04735978Advanced Solid Tumor
DrugNivolumab
Replimune, Inc.
Phase 1
123
Iowa, Pennsylvania, Texas
2020-12-29
Active, closed
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
NCT04592653Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Mural Oncology, Inc
Phase 1/2
78
Michigan, Texas, Utah, Virginia
2020-09-30
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Arizona, Florida, Minnesota, Texas
2020-09-08
Active, closed
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Turning Point Therapeutics, Inc.
Phase 1
95
California, Colorado, Illinois, Massachusetts, Michigan, Missouri, Ohio, Texas
2019-09-05
Rows per page Showing 1–87 of 87
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 87 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

61 of the 87 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 23 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 87 studies
PhaseStudiesRecruitingShare
Phase 1523759.8%
Phase 1/2332437.9%
Phase 2101.1%
Phase 3101.1%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
BeOne Medicines1010
EMD Serono Research & Development Institute, Inc.32
OncoC4, Inc.32
TORL Biotherapeutics, LLC31
Daiichi Sankyo21
Gilead Sciences21
Ipsen21
OBI Pharma, Inc21
PharmaMar21
1ST Biotherapeutics, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.